Skip to main content
SpringerLink
Log in

Medikamentöse Therapie dermatologischer Erkrankungen

Wann muss ein Androloge wie beraten?

Drug treatment of dermatological disorders

Aspects to consider from an andrological perspective

  • Leitthema
  • Published:
Der Hautarzt Aims and scope Submit manuscript

Zusammenfassung

Die Besprechung dermatologischer Systemtherapien führt nicht nur im onkologischen Bereich regelmäßig zur Frage nach deren Auswirkungen auf die männliche Fertilität. Gerade bei neueren Medikamenten ist die Datenlage zu gonadotoxischen und anderen fertilitätsrelevanten Aspekten limitiert. Darüber hinaus bestehen individuelle Suszeptibilitätsunterschiede und eine Abhängigkeit von andrologischen Vorerkrankungen. Zur Fertilitätsprotektion kommt neben der Auswahl fertilitätsschonender Medikamente eine Spermienkryokonservierung in Betracht.

Abstract

Dermatologists administer a broad spectrum of systemic medications. However, our current knowledge of potential risks to male fertility is still limited, particularly with the new emerging therapies in dermato-oncology. Individual differences in susceptibility and a history of andrological disorders influence prognostic values. For fertility protection, a thoughtful selection of medication and/or sperm cryopreservation remain the best options.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Abb. 1

Literatur

  1. Adeeko AO, Dada OA (1994) Chloroquine excretion in semen following antimalarial-drug administration. Andrologia 26:165–166

    Article  CAS  PubMed  Google Scholar 

  2. Adler ID, Kliesch U, Jentsch I et al (2002) Induction of chromosomal aberrations by dacarbazine in somatic and germinal cells of mice. Mutagenesis 17:383–389

    Article  CAS  PubMed  Google Scholar 

  3. Albarel F, Gaudy C, Castinetti F et al (2015) Long-term follow-up of ipilimumab-induced hypophysitis, a common adverse event of the anti-CTLA-4 antibody in melanoma. Eur J Endocrinol 172:195–204

    Article  CAS  PubMed  Google Scholar 

  4. Buchanan JD, Fairley KF, Barrie JU (1975) Return of spermatogenesis after stopping cyclophosphamide therapy. Lancet 2:156–157

    Article  CAS  PubMed  Google Scholar 

  5. Bujan L, Walschaerts M, Brugnon F et al (2014) Impact of lymphoma treatments on spermatogenesis and sperm deoxyribonucleic acid: a multicenter prospective study from the CECOS network. Fertil Steril 102:667–674

    Article  CAS  PubMed  Google Scholar 

  6. Cutolo M, Giusti M, Villaggio B et al (1997) Testosterone metabolism and cyclosporin A treatment in rheumatoid arthritis. Br J Rheumatol 36:433–439

    Article  CAS  PubMed  Google Scholar 

  7. Dillard T, Yedinak CG, Alumkal J et al (2010) Anti-CTLA-4 antibody therapy associated autoimmune hypophysitis: serious immune related adverse events across a spectrum of cancer subtypes. Pituitary 13:29–38

    Article  CAS  PubMed  Google Scholar 

  8. Donnelly ET, McClure N, Lewis SE (2001) Cryopreservation of human semen and prepared sperm: effects on motility parameters and DNA integrity. Fertil Steril 76:892–900

    Article  CAS  PubMed  Google Scholar 

  9. Geiger JM, Walker M (2002) Is there a reproductive safety risk in male patients treated with acitretin (neotigason/soriatane? Dermatology 205:105–107

    Article  CAS  PubMed  Google Scholar 

  10. Gromnica-Ihle E, Kruger K (2010) Use of methotrexate in young patients with respect to the reproductive system. Clin Exp Rheumatol 28:S80–S84

    CAS  PubMed  Google Scholar 

  11. Grunewald S, Jank A (2015) New systemic agents in dermatology with respect to fertility, pregnancy, and lactation. J Dtsch Dermatol Ges 13:277–289

    PubMed  Google Scholar 

  12. Grunewald S, Paasch U, Glander HJ (2007) Systemic dermatological treatment with relevance for male fertility. J Dtsch Dermatol Ges 5:15–21

    Article  PubMed  Google Scholar 

  13. Hargreaves CA, Rogers S, Hills F et al (1998) Effects of co-trimoxazole, erythromycin, amoxycillin, tetracycline and chloroquine on sperm function in vitro. Hum Reprod 13:1878–1886

    Article  CAS  PubMed  Google Scholar 

  14. Hyrich KL, Verstappen SM (2014) Biologic therapies and pregnancy: the story so far. Rheumatology (Oxford) 53:1377–1385

    Article  CAS  Google Scholar 

  15. Karamfilov T, Wollina U, Hipler UC et al (2000) Effects of adjuvant interferon-alpha low-dose therapy in melanoma patients on serum inhibin B. J Dermatol 27:639–642

    Article  CAS  PubMed  Google Scholar 

  16. Ligumsky M, Badaan S, Lewis H et al (2005) Effects of 6-mercaptopurine treatment on sperm production and reproductive performance: a study in male mice. Scand J Gastroenterol 40:444–449

    Article  CAS  PubMed  Google Scholar 

  17. Micu MC, Micu R, Surd S et al (2014) TNF-alpha inhibitors do not impair sperm quality in males with ankylosing spondylitis after short-term or long-term treatment. Rheumatology (Oxford) 53:1250–1255

    Article  CAS  Google Scholar 

  18. Millsop JW, Heller MM, Eliason MJ et al (2013) Dermatological medication effects on male fertility. Dermatol Ther 26:337–346

    Article  PubMed  Google Scholar 

  19. Naz RK, Chauhan SC, Rose LP (2000) Expression of alpha and gamma interferon receptors in the sperm cell. Mol Reprod Dev 56:189–197

    Article  CAS  PubMed  Google Scholar 

  20. Paschou S, Voulgari PV, Vrabie IG et al (2009) Fertility and reproduction in male patients with ankylosing spondylitis treated with infliximab. J Rheumatol 36:351–354

    PubMed  Google Scholar 

  21. Rivkees SA, Crawford JD (1988) The relationship of gonadal activity and chemotherapy-induced gonadal damage. JAMA 259:2123–2125

    Article  CAS  PubMed  Google Scholar 

  22. Said TM, Agarwal A, Falcone T et al (2005) Infliximab may reverse the toxic effects induced by tumor necrosis factor alpha in human spermatozoa: an in vitro model. Fertil Steril 83:1665–1673

    Article  CAS  PubMed  Google Scholar 

  23. Sakamoto Y, Matsumoto T, Kumazawa J (1998) Cell-mediated autoimmune response to testis induced by bilateral testicular injury can be suppressed by cyclosporin A. J Urol 159:1735–1740

    Article  CAS  PubMed  Google Scholar 

  24. Sands K, Jansen R, Zaslau S et al (2015) Review article: the safety of therapeutic drugs in male inflammatory bowel disease patients wishing to conceive. Aliment Pharmacol Ther 41:821–834

    Article  CAS  PubMed  Google Scholar 

  25. Shash E, Bassi S, Cocorocchio E et al (2011) Fatherhood during imatinib. Acta Oncol 50:734–735

    Article  PubMed  Google Scholar 

  26. Teruel C, Lopez-San RA, Bermejo F et al (2010) Outcomes of pregnancies fathered by inflammatory bowel disease patients exposed to thiopurines. Am J Gastroenterol 105:2003–2008

    Article  CAS  PubMed  Google Scholar 

  27. Torino F, Barnabei A, Paragliola RM et al (2013) Endocrine side-effects of anti-cancer drugs: mAbs and pituitary dysfunction: clinical evidence and pathogenic hypotheses. Eur J Endocrinol 169:R153–R164

    Article  CAS  PubMed  Google Scholar 

  28. Tran TA, Kone-Paut I, Marie I et al (2012) Muckle-Wells syndrome and male hypofertility: a case series. Semin Arthritis Rheum 42:327–331

    Article  PubMed  Google Scholar 

  29. Villiger PM, Caliezi G, Cottin V et al (2010) Effects of TNF antagonists on sperm characteristics in patients with spondyloarthritis. Ann Rheum Dis 69:1842–1844

    Article  CAS  PubMed  Google Scholar 

  30. Whirledge S, Cidlowski JA (2010) Glucocorticoids, stress, and fertility. Minerva Endocrinol 35:109–125

    PubMed Central  CAS  PubMed  Google Scholar 

  31. Yavetz H, Yogev L, Homonnai Z et al (1991) Prerequisites for successful human sperm cryobanking: sperm quality and prefreezing holding time. Fertil Steril 55:812–816

    CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Klinik für Dermatologie, Venerologie und Allergologie, Universitätsklinikum Leipzig AöR, Ph.-Rosenthal-Str. 23, 04103, Leipzig, Deutschland

    S. Grunewald & U. Paasch

Authors
  1. S. Grunewald
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. U. Paasch
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to S. Grunewald.

Ethics declarations

Interessenkonflikt

S. Grunewald und U. Paasch geben an, dass kein Interessenkonflikt besteht.

Dieser Beitrag beinhaltet keine Studien an Menschen oder Tieren.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Grunewald, S., Paasch, U. Medikamentöse Therapie dermatologischer Erkrankungen. Hautarzt 66, 913–918 (2015). https://doi.org/10.1007/s00105-015-3706-x

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00105-015-3706-x

Schlüsselwörter

Keywords

Search

Navigation